A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer

Phase 2 Completed 126 enrolled Lund University Hospital South Sweden Breast Cancer Group · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment with Focus on Mechanisms of Resistance to Endocrine Treatment (fulvestrant/aromatase inhibitors) in Patients With Advanced Breast Cancer.

Timeline

Start: 2025-01-02
Primary completion: 2025-01-02
Completion: 2025-01-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atorvastatin	Small molecule	40 mg	Oral
Comparator	Letrozole	Other / unclassified	2.5 mg	Oral
Background	Fulvestrant	Small molecule	—	—

A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer

Summary

Timeline

Drugs

Indications